Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptibleEscherichia colibloodstream infection

BACKGROUND: Cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, intravenous fosfomycin and plazomicin represent potential carbapenem sparing agents for extended-spectrum-beta-lactamase or AmpC beta-lactamase producing Escherichia coli infection. However, available data is limited in predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Ouli, Cisera, Kathryn, Taylor, Lucy, Hughes, Carly, Rogers, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708213/
https://www.ncbi.nlm.nih.gov/pubmed/33256752
http://dx.doi.org/10.1186/s12941-020-00400-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708213/
https://www.ncbi.nlm.nih.gov/pubmed/33256752
http://dx.doi.org/10.1186/s12941-020-00400-z

Ejemplares similares